Browse > Article

Single-dose Pharmacokinetics of Garenoxacin in Healthy Korean Volunteers  

Shin, Dong-Hoon (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Hong, Jeong-Hwa (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Yi, So-Jeong (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Kim, Tae-Eun (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.18, no.1, 2010 , pp. 43-52 More about this Journal
Abstract
Background: Garenoxacin is a des-F(6) quinolone antimicrobial drug with broad-spectrum activity. We investigated the safety and pharmacokinetic (PK) characteristics of garenoxacin after a single oral dose in healthy Korean male volunteers, and compared them to those of Japanese. Methods: A parallel, single ascending dose (200, 400 and 600 mg), dose-block randomized, double-blind, placebo-controlled study was conducted in 24 healthy Korean male volunteers. Subjects were randomized into each dose group (6 for active drug, 2 for placebo). For safety assessment, vital signs, laboratory tests, 12-lead electrocardiograms and adverse events were monitored. Plasma concentrations of garenoxacin were measured till 72 hours after drug administration. Concentration-time data was analyzed by noncompartmental methods and the results were compared to Japanese data from the previous study performed under the same protocol. Results: Regarding safety, all doses of garenoxacin were well tolerated without serious adverse events or clinically meaningful changes. The mean area under the concentration-time curve from 0 hour to the last measured concentration over the limit of quantitation ($C_{last}$) ($AUC_{last}$) were 43.9, 101.8, 155.7 mg*h/L and the maximum plasma concentration ($C_{max}$) were 4.7, 8.9, 13.6 mg/L in 200, 400 and 600 mg dose groups, respectively. The range of mean elimination half-life by dose groups was 12.3 to 12.4 h. Increases in systemic exposure to garenoxacin in terms of $AUC_{last}$ and $C_{max}$ were dose proportional over the dose range of 200 to 600 mg. The geometric mean ratios (90% confidence interval) for Koreans to Japanese were 0.97 (0.87-1.08) for dose-normalized $AUC_{last}$ and 1.08 (0.96-1.22) for dose-normalized $C_{max}$. Conclusion: Single oral doses of garenoxacin were well tolerated. Systemic exposures of garenoxacin were linear according to dose increments up to 600 mg dose. Comparison of the PK between Koreans and Japanese indicates that the pharmacokinetic characteristics were similar, which suggests that no dosage adjustment is required for garenoxacin in Koreans compared to Japanese.
Keywords
Garenoxacin; Clinical trial; Pharmacokinetics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Krishna G, Kisicki JC, Olsen S, Grasela DM, Wang Z. The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers. J Clin Pharmacol, 2007;47:628-632.   DOI   ScienceOn
2 Azoulay-Dupuis E, Bedos JP, Mohler J, Peytavin G, Isturiz R, Moine P, Rieux V, Cherbuliez C, Pechere JC, Fantin B, Kohler T. Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob Agents Chemother, 2004;48:765-773.   DOI   ScienceOn
3 Ethnic Factors in the Acceptability of Foreign Clinical Data: ICH Harmonised Tripartite Guideline. Ethnic factors in the acceptability of foreign clinical data: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1998.
4 가교자료평가 가이드라인, 식품의약품안전청, 2008.
5 Bertino J, Fish D. The Safety Profile of the Fluoroquinolones. Clin Ther, 2000;22:798-816.   DOI   ScienceOn
6 Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, Kuroiwa H, Nishigaki J, Tsuji A. Metabolism and Disposition of Novel Des-Fluoro Quinolone Garenoxacin in Experimental Animals and an Interspecies Scaling of Pharmacokinetic Parameters. Drug Metab Dispos, 2003;31:1409-1418.   DOI   ScienceOn
7 Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Frgue ST. Confidence Interval Criteria for Assessment of Dose Proportionality. Pharm Res, 2000;17:1278-1283.   DOI   ScienceOn
8 Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob Agents Chemother, 2003;47:2256-2263.   DOI   ScienceOn
9 Takagi H, Tanaka K, Tsuda H, Kobayashi H. Clinical studies of garenoxacin. Int J Antimicrob Agents, 2008;32:468-474.   DOI   ScienceOn
10 Pereyre S, Renaudin H, Bebear C, Bebear CM. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob Agents Chemother, 2004;48:3165-3168.   DOI   ScienceOn
11 American Thoracic Society Documents. Guidlines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med, 2005;171:388-416.   DOI   ScienceOn
12 Wang Z, Grasela DM, Krishna G. Retrospective Analysis of Electrocardiogram Changes After Administration of Oral or Intravenous Garenoxacin in Five Phase I, Placebo-Controlled Studies in Healthy Volunteers. Clin Ther, 2007;29:1098-1106.   DOI   ScienceOn
13 Jones RN, Sader HS, Stilwell MG, Fritsche TR. Garenoxacin activity against isolates form patients hospitalized with communityacquired pneumonia and multidrug-resistant Streptococcus pneumonia. Diagn Microbiol Infect Dis, 2007;58:1-7.   DOI   ScienceOn
14 Andriole VT. The Quinolones: Past, Present, and Future. Clin Infect Dis, 2005;41:S113-S119.   DOI   ScienceOn
15 Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ. A Review of New Fluoroquinolones. Treat Respir Med, 2006;5:437-465.   DOI
16 Investigator's Brochure: 동아 Garenoxacin 정. 동아제약주식회사. 2007.
17 Mandell LA, Wundrink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis, 2007;44:S27-S72.   DOI   ScienceOn